Mednow Investor Presentation Deck

Investment Highlights - 2022 & 2023 Forecasts Show Strong Growth 2022 Calendar Full-Year Forecast $42.5 - $47.5M Revenue 20% Gross Margin Negative Adjusted EBITDA Margin 40K - 45K Active Patients (define with active in last 24 months) mednow I TSX-V: MNOW I OTC-QB: MDNWF 2023 Calendar Full-Year Forecast $105 - $110 M Revenue 25% Gross Margin $5 - $10 Million Adjusted EBITDA 110K - 120K Active Patients (define with active in last 24 months) 1. Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization and transaction costs; EBITDA is not a recognized measure under Canadian generally accepted accounting principles; management believes however that Adjusted EBITDA is a useful supplementary measure as it provides indication of the results of Mednow's business operations; please refer to disclaimer on page 2 regarding Non-IFRS Measures. 7

View entire presentation